These results are of significance because recombinant human DNase I has been used in the clinical setting for patients with pulmonary diseases, such as cystic fibrosis and pneumonia, and has shown excellent safety and efficacy [35, 36]; however, the mechanisms underlying these protective effects are likely different from the actions reported herein. Here, DNASE1 is linked to cystic fibrosis.